Skip to main content

Bet on BBH for Biotechnology Bounce Back

Biotechnology equities are lagging the healthcare sector and the broader market this year, but with new variants of the coronavirus expected to continue popping up in 2022, it’s impossible to ignore biotech assets as a potential rebound idea. That includes the VanEck Vectors Biotech ETF...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.